Paula L. McClean

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

Theresa R. Bomfim, Letícia Forny‐Germano, Luciana B. Sathler et al. · Journal of Clinical Investigation · 2012 · 812 citations · Full text

Synaptic Transmission, Synaptic Signaling, Insulin Signaling +28

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

Paula L. McClean, Vadivel Parthsarathy, Émilie Faivre et al. · Journal of Neuroscience · 2011 · 678 citations · Full text

Aging, Synaptic Transmission, Neurochemical Biomarkers +24

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

Paula L. McClean, Christian Hölscher · Neuropharmacology · 2013 · 340 citations

Alzheimer's Disease, Aging, Aged App/ps1 Mice +10

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

Paula L. McClean, Nigel Irwin, Roslyn Cassidy et al. · American Journal of Physiology-Endocrinology and Metabolism · 2007 · 232 citations

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

Paula L. McClean, Victor A. Gault, Patrick Harriott et al. · European Journal of Pharmacology · 2009 · 185 citations

Synaptic Plasticity, Alzheimer's Disease, Diabetes +8